EL7.AI
StocksMedium•28 September 2026•
1 min read

Cosmos Health Achieves Record Growth in Contract Manufacturing Pipeline

Key Facts

1Cosmos Health's subsidiary Cana Laboratories surpassed $20 million in implied revenue within its contract manufacturing pipeline.
2The production pipeline reached a record 32.7 million units, increasing approximately sixfold since mid-2024.
3The company expects gross margins exceeding 90% from these contracts, supporting its 2029 financial guidance.

Cosmos Health announced that its subsidiary Cana Laboratories has surpassed $20 million in implied revenue within its contract manufacturing pipeline. ACCESS Newswire reported that the production pipeline reached a record 32.7 million units, representing an approximately sixfold increase since mid-2024. The company stated that this growth is driven by multi-year agreements across 11 therapeutic categories, with 7.7 million units added in September 2026 alone.

The company expects gross margins to exceed 90% from these contracts, supporting its 2029 financial guidance. In the equity markets, COSM closed at $0.3516 on September 25, 2026. This operational expansion highlights the company's efforts to secure high-margin revenue visibility through its manufacturing division.